News

New combination therapy for ovarian cancer shows positive r...

New combination therapy for ovarian cancer shows positive results in Phase I clinical trials

January 7, 2014

A new combination therapy developed by researchers at the Roswell Park Cancer Institute has showed positive results in 60% of women with recurrent ovarian cancer. To develop the new therapy, researchers took advantage of the fact that ovarian cancer cells have abnormally high a marker called NY-ESO-1 on their surfaces. Researchers gave patients a drug … Continued

Research

OCRF Research Finds New “Chemoimmunotherapy” Ma...

OCRF Research Finds New “Chemoimmunotherapy” May Be New Treatment Option

January 6, 2014

New research funded by OCRF shows that treatment with the drug decitabine, prior to administration of chemotherapy and a cancer vaccine, yielded clinical benefit for women with recurrent ovarian cancer. This suggests that this combinatorial “chemoimmunotherapy” may provide a new treatment option for patients with this disease. Results of this phase I clinical trial, which … Continued

OCRA News

New Guidelines on Risk, Genetic Counseling & Testing f...

New Guidelines on Risk, Genetic Counseling & Testing for BRCA-related Cancer

December 30, 2013

(December 30, 2013)   The U.S. Preventive Services Task Force (Task Force) has issued a final recommendation statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-related Cancer in Women. This final recommendation statement applies to women who have no signs or symptoms of a BRCA-related cancer (cancer of the breast, ovary, fallopian tube, or … Continued

Research

High Volume Hospitals and Providers Improve Survival

High Volume Hospitals and Providers Improve Survival

December 20, 2013

(December 20, 2013)  Researchers have found that for women with advanced-stage ovarian cancer, being treated at a high volume hospital with a high volume provider, leads to improved survival.  The research was published online today in Gynecologic Oncology. Among patients with advanced-stage ovarian cancer, the provider combination of high volume hospital/high volume provider is an … Continued

Research

Partner Member Profile: Hope for Heather

Partner Member Profile: Hope for Heather

December 20, 2013

Hope for Heather was established in memory of Heather Weeks, a young woman who lost her life to colon cancer but spent her 20s working on behalf of women with ovarian cancer. Heather’s family started the organization in March of 2009. Their original goal was to raise about $1,000 a year for ovarian cancer research; … Continued

Community

Treatment in New Study on Mice with Ovarian Cancer has Posi...

Treatment in New Study on Mice with Ovarian Cancer has Positive Results

December 17, 2013

A targeted drug delivery system developed at Rutgers University could possibly make ovarian cancer more treatable.  The study results published in Clinical Cancer Research also indicated the new system could increase survival rates in ovarian cancer.  Read the full article here.    

Research

New OCRF Research on Ovarian Cancer Proliferation, Migratio...

New OCRF Research on Ovarian Cancer Proliferation, Migration, and Response to Therapy

December 11, 2013

Research funded by Ovarian Cancer Research Fund shows that adipose derived stromal cells derived from the human omentum can promote ovarian cancer proliferation, migration, chemoresistance and radiation resistance in-vitro. The research, funded in part through an OCRF grant to senior author Ann Klopp, MD, PhD was published online last week in PLoS One. The researchers hypothesized … Continued

Research

OCRF Research Sheds Light on Ovarian Cancer Origins in BRCA...

OCRF Research Sheds Light on Ovarian Cancer Origins in BRCA Mutation Carriers

December 10, 2013

A team of current and former OCRF grantees at Brigham and Women’s Hospital, Harvard Medical School and Dana-Farber Cancer Institute has developed genetically engineered mouse models of high-grade serous ovarian cancer that shed light on the pathogenesis of ovarian cancer for BRCA1/2 mutation carriers.  These models, which target the cell of origin (fallopian tube secretory cells) and recreate key genetic … Continued

OCRA News

Then & Now: 20 Years and Still Going Strong

Then & Now: 20 Years and Still Going Strong

December 9, 2013

OCRF Board Member, Robin Zarel, Celebrates 20 Years as an Ovarian Cancer Survivor.

OCRA News

Supreme Court to Consider Two Birth Control Lawsuits

Supreme Court to Consider Two Birth Control Lawsuits

December 3, 2013

The Supreme Court recently announced that it will hear two cases involving insurance coverage for birth control. The Alliance weighed in on one of these cases, arguing that oral contraceptives are a proven way to prevent ovarian cancer and should therefore be made available to women who wish to reduce their risk. Our CEO Calaneet … Continued

Advocacy

Scientists Ask: Does Ovarian Cancer Have a Smell?

Scientists Ask: Does Ovarian Cancer Have a Smell?

November 25, 2013

George Preti, who works at the Monell Chemical Senses Center as an organic chemist, and an interdisciplinary team that includes physicists and veterinarians at the University of Pennsylvania are using an electronic box to explore whether cancer has a smell.  In diseases that affect our metabolism, we secrete smells that can be indicative of what … Continued

Research

Partner Member Profile: Ovacome

Partner Member Profile: Ovacome

November 25, 2013

In 1999, Frieda Hooper was diagnosed with ovarian cancer. Frustrated with the lack of educational and supportive resources available, Hooper formed a support group for women with ovarian cancer in the Tampa Bay area, under the American Cancer Society. Rapidly growing in popularity, Ovacome started meeting independently of the American Cancer Society, eventually becoming an … Continued

Community